What drug a GLP-1 price is for

What the figures name

Each of the 3018 figures was read with the words around it, by a person, and recorded against the drug those words name. Four outcomes, summing to 3018.

337 figures say a GLP-1 and stop. That is not a small category and it is not an accident of the reading: “GLP-1” is a class of drug, and a class is what a page says when it wants a number to look like an offer without committing to what the offer is. Semaglutide and tirzepatide are not interchangeable, they are not priced alike, and their labels do not say the same things — what the FDA-approved labels state about each is on this site with no company named.

Which brand-name drugs get a price

320 of the 3018 figures name one of 6 brand-name products. These are the only figures on which the question this page asks has already been answered by the drug’s own name.

A brand name is a trademark of its manufacturer and is used here only to identify the product a seller’s own page named. This site is not affiliated with any of them; see trademarks.

Where the figure was read

A second question, asked of the same 3018 figures: was the number read on a page about one drug, or on a general page — a home page, a pricing page, a landing page — that happens to mention a GLP-1 somewhere near it?

523 figures were read on a general or home page. This site prints none of them, and the reason is not that they are wrong. It is that they are unshowable: to publish a figure honestly you have to be able to quote the words that make it true, and on a home page carrying several drugs, several plans and several prices, no short quotation proves which number goes with which drug. A page that printed them anyway would be asking a reader to trust a tie it could not show.

The same question, asked once per seller

Everything above counts figures. This section counts sellers, and the denominator is 408 — the sellers that published at least one figure this reading could tie to a GLP-1, not the 588 whose pages were opened and not the roster.

56 sellers never name a drug beside any figure they publish, and 115 have no page about a drug at all. Against that, 94 publish at least one figure naming a brand-name product and 304 publish at least one naming semaglutide or tirzepatide. The rows overlap on purpose: a seller can name a drug on one page and not on another, and collapsing that into a single verdict per company would hide the thing worth knowing.

Why none of these numbers is printed as a price

Not one amount appears on this page, and the module behind it holds none. That is a rule, not an omission. A figure earns a place on this site when three things can be shown at once: the seller’s own words contain the number, those words identify the drug, and the qualifier that makes the number true can be printed beside it.

Most of these 3018 figures fail the second test, and there is no fixing it by reading harder. Where the tie between a number and a drug rests on layout — a heading three blocks up, a tab that was open when the page loaded — the tie is real to a person sitting in front of the page and cannot be carried to a reader in a quotation. The honest response is to count them and print the count, which is what this page is.

Prices on this site come from the 60 sellers whose figure states what it buys, each shown with the seller’s own qualifier attached. How many sellers that is out of, and every rule that narrows one number to the other, is on how many GLP-1 sellers publish a price.

The other findings

Each is counted over its own set, and the sets are different sizes on purpose. The denominator is printed beside every one.

• How many sellers publish a price

  What happened when the pages of every GLP-1 seller we could find were opened and read: how many published a figure at all, and how many published one that can be compared.

  Counted over 588 sellers whose pages were opened.

• Compounded or branded

  How often a seller says, beside the figure, whether the drug is compounded or the FDA-approved product — and the one case where it almost always does.

  Counted over 3018 published figures across 408 sellers.

• What sellers do not publish

  The pharmacy, the product class, the dose schedule and the cancellation terms: four things a reader needs before buying, counted as absences with a denominator attached.

  Counted over 60 sellers whose figure states what it buys.

• The tirzepatide premium

  What the same seller charges for tirzepatide against semaglutide — and why most sellers who sell both do not publish a pair a reader can put side by side.

  Counted over 46 sellers publishing a figure for both molecules.

• What a price buys, by dose

  Whether a GLP-1 price changes with the dose, and how many sellers publish a figure that states which dose it buys at all.

  Counted over 60 of 117 sellers on this roster.

What the FDA labels say

What each of these drugs is approved to treat, how its dose escalates and who should not take it is read from the FDA-approved prescribing information, with no company named and no paid link.

• Semaglutide vs tirzepatidereading the label

  What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.

• Dose escalation schedulesreading the label

  The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.

• Side effect ratesreading the label

  What each label reports for nausea, vomiting, diarrhoea and constipation — and the sentence every label prints above those numbers.

• Missed dose rulesreading the label

  The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.

• Drug interactionsreading the label

  Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.

• Buying one onlinereading the label

  The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.

• Who should not take onereading the label

  The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.

Where the comparable sellers are compared

One board per buying decision, built only from the sellers whose figure names a drug and states what it buys.

• Semaglutide providers54 listed, September 2026

  Readers who have settled on semaglutide and are choosing who to buy it from.

• Tirzepatide providers52 listed, September 2026

  Readers who have settled on tirzepatide and are choosing who to buy it from.

• Providers that publish a price before the intake59 listed, September 2026

  Readers who will not start an intake without seeing a standing rate and what it covers.

• GLP-1 providers with a published price, compared59 listed, September 2026

  Readers whose first question is the number, and who want to see what each figure actually buys before comparing them.

• GLP-1 providers for readers paying cash52 listed, September 2026

  Readers who are paying out of pocket and need the medication itself inside the published figure, not just the consult.

• GLP-1 telehealth providers60 listed, September 2026

  Readers choosing a prescriber rather than a price — who dispenses, what the plan includes, and how to leave it.